11:33 AM EST - PharmaGap Inc. : announced that liposomal formulations of its cancer drug have proven to meet and surpass expectations for three key elements important for clinical trials -- potency, pharmacokinetic profile, and therapeutic index. Peptide half-life has been increased from a range of 0.4 to 0.7 for unformulated peptides to approximately eight hours using intravenous administration and to approximately 40 hours using intraperitoneal administration. Liposomal associated peptide was detectable up to 72 hours post administration indicating that peptide remains in circulation for extended periods of time. PharmaGap Inc.
shares V.GAP are trading up $0.01 at $0.08.
